Related Experiment Video

Updated: Feb 4, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles

Bhaskar Venkata Kameswara Subrahmanya Lakkakula1, Batoul Farran2, Saikrishna Lakkakula3

  • 1SCIC, Pt. JNM Medical College, Raipur, CG-492001, India.

Seminars in Cancer Biology
|October 14, 2018
PubMed

Insights

Pancreatic cancer (PC) management faces challenges with unresectable disease. This review examines small molecule tyrosine kinase inhibitors (TKIs) for PC, highlighting acquired resistance issues.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Pancreatic cancer (PC) is a leading cause of cancer mortality in Western nations.
  • Surgical resection is the primary treatment, but many cases are unresectable or locally advanced, posing significant management challenges.
  • Advances in understanding PC biology have spurred the development of targeted therapies.

Purpose of the Study:

  • To review clinical trials investigating small molecule tyrosine kinase inhibitors (TKIs) for pancreatic cancer treatment.
  • To discuss the challenges and acquired resistance mechanisms associated with TKI therapy in PC management.

Main Methods:

  • Literature review of clinical trials and research studies on TKIs in pancreatic cancer.
  • Analysis of data concerning TKI efficacy, resistance patterns, and therapeutic outcomes.
  • Synthesis of current knowledge on pancreatic tumor biology and targeted therapy pathways.

Main Results:

  • Small molecule TKIs represent a developing treatment modality for controlling metastatic pancreatic cancer spread.
  • Acquired resistance to TKIs is a significant and inevitable challenge in the clinical application of these drugs.
  • Understanding resistance mechanisms is crucial for improving long-term patient outcomes.

Conclusions:

  • Targeted therapies, including TKIs, offer potential for managing advanced pancreatic cancer.
  • Overcoming acquired resistance is paramount for the successful clinical implementation of TKIs in PC treatment.
  • Further research is needed to develop strategies to circumvent TKI resistance and improve therapeutic efficacy.
Keywords:
Clinical trialsPancreatic carcinomaResistanceTargeted therapiesTyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening07:18

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

6.8K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
534
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K